Navigation Links
HemoShear to Present at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Conference

CHARLOTTESVILLE, Va., April 16, 2012 /PRNewswire/ -- HemoShear, LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, has been invited to present at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) conference.  The conference will be held April 18-20, 2012 at the Hilton Chicago, 720 South Michigan Avenue in Chicago, Illinois.

(Logo: )

The company will occupy booth No. six for recruiting purposes and present two scientific abstracts:

Atheroprone Hemodynamics and Oxidized Phospholipids Enhance Endothelial and Smooth Muscle Inflammatory Signaling

  • Presentation Date and Time: April 18th from 5:30pm to 7:30pm
  • Abstract ID Number: 580
  • Poster Presentation Number: 179
  • Presenter:  Ryan Feaver, Ph.D., HemoShear, Scientific Director

The Thrombotic Potential of the Endothelium Is Regulated by Hemodynamic Flow

  • Presentation Date and Time: April 20th from 8:00am to 10:00am
  • Abstract ID Number: 588
  • Poster Presentation Number: 521
  • Presenter:  Michael Simmers, Ph.D., HemoShear, Scientific Director

HemoShear team members attending the conference include Brett Blackman, Ph. D., co-founder, Chief Scientific Officer; Brian Wamhoff, Ph.D., co-founder, Vice President of Research and Development; Nicole Hastings, Ph.D., Vice President of Operations; Ryan Feaver, Ph.D., Scientific Director; Michael Simmers, Ph.D., Scientific Director.

About HemoShear, LLC

HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases throughout drug discovery and development.  Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies.  HemoShear's science leads to new medicines and improves human health.  

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
5. Bionovo to Present at Canaccord Adams Global Growth Conference
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
10. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
11. Cepheid to Webcast Upcoming Financial Presentations
Post Your Comments:
(Date:11/24/2015)... /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: ... Pierre Laurin , President and Chief Executive Officer of ProMetic, ... Jaffray 27 th Annual Healthcare Conference to be held ... st , at 8.50am (ET) and ProMetic,s ... day. The presentation will be available live via a webcast ...
(Date:11/24/2015)... and NEW YORK , November ... irst investment by Bristol-Myers Squibb in a European ... Bristol-Myers Squibb Company in which the companies will ... in immuno-oncology and other areas of unmet medical need. The ... in LSP 5, the latest LSP fund. This is the ...
(Date:11/23/2015)... OAKS, Calif., Nov. 23, 2015   Ceres, Inc ... announced today financial results for the fiscal year ended ... business. --> --> ... commercializing forage and feed products with a better balance ... company signed distribution agreements with several leading crop input ...
(Date:11/23/2015)... -- The royalty-free a greement a ... daclatasvir for 112 low- and m iddle-i ... --> The Medicines Patent Pool (MPP) today ... an agreement with Bristol-Myers Squibb for daclatasvir, a novel direct-acting ... the HCV virus.  The royalty-free licence will enable generic manufacture ...
Breaking Biology Technology:
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
Breaking Biology News(10 mins):